Finally, further elucidation of potential Itpkb roles in Alzheimer’s disease (176, 177), multiple sclerosis (178), and malignant melanoma (179) might unveil additional therapeutic opportunities or liabilities for selective Itpkb inhibitors. This evidence concerns the gene ITPKB and early-onset autosomal dominant Alzheimer disease.